APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Tuberculosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Tuberculosis Drug Market Outlook and Growth Opportunities 2026

31 December 2025197 pages

Choose your research edition.

Industry ResearchAnti-Tuberculosis Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Tuberculosis Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Anti-Tuberculosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Tuberculosis Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Tuberculosis Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Anti-Tuberculosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Tuberculosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Tuberculosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Tuberculosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Tuberculosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Tuberculosis Drug market include Abbott, Sanofi, NOVARTIS, Prizer, Otsuka and Lupin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Tuberculosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Tuberculosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Tuberculosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Tuberculosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Tuberculosis Drug Segment by Company

Abbott

Sanofi

NOVARTIS

Prizer

Otsuka

Lupin

Anti-Tuberculosis Drug Segment by Type

First-Line Anti-Tuberculosis Drugs

Second-Line Anti-Tuberculosis Drugs

Anti-Tuberculosis Drug Segment by Application

Hospital

Clinic

Others

Anti-Tuberculosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anti-Tuberculosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Tuberculosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Tuberculosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Tuberculosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Tuberculosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Tuberculosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Tuberculosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Tuberculosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Tuberculosis Drug industry.

Chapter 3: Detailed analysis of Anti-Tuberculosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Tuberculosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Tuberculosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Tuberculosis Drug Industry Trends Table 2. Anti-Tuberculosis Drug Industry Drivers Table 3. Anti-Tuberculosis Drug Industry Opportunities and Challenges Table 4. Anti-Tuberculosis Drug Industry Restraints Table 5. Global Anti-Tuberculosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Tuberculosis Drug Revenue Share by Company (2021-2026) Table 7. Global Anti-Tuberculosis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anti-Tuberculosis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Tuberculosis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anti-Tuberculosis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Tuberculosis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Tuberculosis Drug Company, Product Type & Application Table 13. Global Anti-Tuberculosis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Tuberculosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of First-Line Anti-Tuberculosis Drugs Table 18. Significant Companies of Second-Line Anti-Tuberculosis Drugs Table 19. Global Anti-Tuberculosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anti-Tuberculosis Drug Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Anti-Tuberculosis Drug Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Anti-Tuberculosis Drug Sales Volume Share by Type (2021-2026) Table 23. Global Anti-Tuberculosis Drug Sales Volume Share by Type (2027-2032) Table 24. Global Anti-Tuberculosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-Tuberculosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-Tuberculosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-Tuberculosis Drug Sales Value Share by Type (2021-2026) Table 28. Global Anti-Tuberculosis Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Anti-Tuberculosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Anti-Tuberculosis Drug Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Anti-Tuberculosis Drug Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Anti-Tuberculosis Drug Sales Volume Share by Application (2021-2026) Table 36. Global Anti-Tuberculosis Drug Sales Volume Share by Application (2027-2032) Table 37. Global Anti-Tuberculosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-Tuberculosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Anti-Tuberculosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Anti-Tuberculosis Drug Sales Value Share by Application (2021-2026) Table 41. Global Anti-Tuberculosis Drug Sales Value Share by Application (2027-2032) Table 42. Global Anti-Tuberculosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Anti-Tuberculosis Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Anti-Tuberculosis Drug Sales Market Share by Region (2021-2026) Table 45. Global Anti-Tuberculosis Drug Sales by Region (2027-2032) & (K Units) Table 46. Global Anti-Tuberculosis Drug Sales Market Share by Region (2027-2032) Table 47. Global Anti-Tuberculosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-Tuberculosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Anti-Tuberculosis Drug Sales Value Share by Region (2021-2026) Table 50. Global Anti-Tuberculosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Anti-Tuberculosis Drug Sales Value Share by Region (2027-2032) Table 52. Global Anti-Tuberculosis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Anti-Tuberculosis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Anti-Tuberculosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Anti-Tuberculosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Anti-Tuberculosis Drug Sales by Country (2021-2026) & (K Units) Table 57. Global Anti-Tuberculosis Drug Sales Market Share by Country (2021-2026) Table 58. Global Anti-Tuberculosis Drug Sales by Country (2027-2032) & (K Units) Table 59. Global Anti-Tuberculosis Drug Sales Market Share by Country (2027-2032) Table 60. Global Anti-Tuberculosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Anti-Tuberculosis Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Anti-Tuberculosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Anti-Tuberculosis Drug Sales Value Market Share by Country (2027-2032) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Anti-Tuberculosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Abbott Anti-Tuberculosis Drug Product Portfolio Table 68. Abbott Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Anti-Tuberculosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Sanofi Anti-Tuberculosis Drug Product Portfolio Table 73. Sanofi Recent Development Table 74. NOVARTIS Company Information Table 75. NOVARTIS Business Overview Table 76. NOVARTIS Anti-Tuberculosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. NOVARTIS Anti-Tuberculosis Drug Product Portfolio Table 78. NOVARTIS Recent Development Table 79. Prizer Company Information Table 80. Prizer Business Overview Table 81. Prizer Anti-Tuberculosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Prizer Anti-Tuberculosis Drug Product Portfolio Table 83. Prizer Recent Development Table 84. Otsuka Company Information Table 85. Otsuka Business Overview Table 86. Otsuka Anti-Tuberculosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Otsuka Anti-Tuberculosis Drug Product Portfolio Table 88. Otsuka Recent Development Table 89. Lupin Company Information Table 90. Lupin Business Overview Table 91. Lupin Anti-Tuberculosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Lupin Anti-Tuberculosis Drug Product Portfolio Table 93. Lupin Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Anti-Tuberculosis Drug Distributors List Table 97. Anti-Tuberculosis Drug Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Anti-Tuberculosis Drug Product Image Figure 2. Global Anti-Tuberculosis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Tuberculosis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Tuberculosis Drug Sales (2021-2032) & (K Units) Figure 5. Global Anti-Tuberculosis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anti-Tuberculosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. First-Line Anti-Tuberculosis Drugs Image Figure 10. Second-Line Anti-Tuberculosis Drugs Image Figure 11. Global Anti-Tuberculosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anti-Tuberculosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-Tuberculosis Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-Tuberculosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-Tuberculosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-Tuberculosis Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Anti-Tuberculosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Anti-Tuberculosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-Tuberculosis Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Anti-Tuberculosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-Tuberculosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-Tuberculosis Drug Sales Value Share by Application (2021-2032) Figure 26. Global Anti-Tuberculosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Anti-Tuberculosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Anti-Tuberculosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Anti-Tuberculosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Anti-Tuberculosis Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Anti-Tuberculosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Anti-Tuberculosis Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Anti-Tuberculosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Anti-Tuberculosis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Anti-Tuberculosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Anti-Tuberculosis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Anti-Tuberculosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Anti-Tuberculosis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Anti-Tuberculosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Anti-Tuberculosis Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Anti-Tuberculosis Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • First-Line Anti-Tuberculosis Drugs
  • Second-Line Anti-Tuberculosis Drugs
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Abbott
  • Sanofi
  • NOVARTIS
  • Prizer
  • Otsuka
  • Lupin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Tuberculosis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Tuberculosis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Tuberculosis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Tuberculosis Drug Market Dynamics
  1. 2.1 Anti-Tuberculosis Drug Industry Trends
  2. 2.2 Anti-Tuberculosis Drug Industry Drivers
  3. 2.3 Anti-Tuberculosis Drug Industry Opportunities and Challenges
  4. 2.4 Anti-Tuberculosis Drug Industry Restraints
3 Anti-Tuberculosis Drug Market by Company
  1. 3.1 Global Anti-Tuberculosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Tuberculosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Tuberculosis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Tuberculosis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Tuberculosis Drug Company Ranking (2024-2026)
  6. 3.6 Global Anti-Tuberculosis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Tuberculosis Drug Company Product Type and Application
  8. 3.8 Global Anti-Tuberculosis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Tuberculosis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Tuberculosis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Tuberculosis Drug Market by Type
  1. 4.1 Anti-Tuberculosis Drug Type Introduction
  2. 4.1.1 First-Line Anti-Tuberculosis Drugs
  3. 4.1.2 Second-Line Anti-Tuberculosis Drugs
  4. 4.2 Global Anti-Tuberculosis Drug Sales Volume by Type
  5. 4.2.1 Global Anti-Tuberculosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-Tuberculosis Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-Tuberculosis Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-Tuberculosis Drug Sales Value by Type
  9. 4.3.1 Global Anti-Tuberculosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-Tuberculosis Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-Tuberculosis Drug Sales Value Share by Type (2021-2032)
5 Anti-Tuberculosis Drug Market by Application
  1. 5.1 Anti-Tuberculosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Anti-Tuberculosis Drug Sales Volume by Application
  6. 5.2.1 Global Anti-Tuberculosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Tuberculosis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anti-Tuberculosis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anti-Tuberculosis Drug Sales Value by Application
  10. 5.3.1 Global Anti-Tuberculosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-Tuberculosis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anti-Tuberculosis Drug Sales Value Share by Application (2021-2032)
6 Anti-Tuberculosis Drug Regional Sales and Value Analysis
  1. 6.1 Global Anti-Tuberculosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Tuberculosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Tuberculosis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Tuberculosis Drug Sales by Region (2027-2032)
  5. 6.3 Global Anti-Tuberculosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Tuberculosis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Tuberculosis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Tuberculosis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Tuberculosis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Tuberculosis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Tuberculosis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Tuberculosis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Tuberculosis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Tuberculosis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Tuberculosis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Tuberculosis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Tuberculosis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Tuberculosis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Tuberculosis Drug Sales Value Share by Country, 2025 VS 2032
7 Anti-Tuberculosis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Tuberculosis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Tuberculosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Tuberculosis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Tuberculosis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Tuberculosis Drug Sales by Country (2027-2032)
  6. 7.4 Global Anti-Tuberculosis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Tuberculosis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Tuberculosis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Tuberculosis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Tuberculosis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Tuberculosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Anti-Tuberculosis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Anti-Tuberculosis Drug Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Anti-Tuberculosis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Anti-Tuberculosis Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 NOVARTIS
  14. 8.3.1 NOVARTIS Company Information
  15. 8.3.2 NOVARTIS Business Overview
  16. 8.3.3 NOVARTIS Anti-Tuberculosis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 NOVARTIS Anti-Tuberculosis Drug Product Portfolio
  18. 8.3.5 NOVARTIS Recent Developments
  19. 8.4 Prizer
  20. 8.4.1 Prizer Company Information
  21. 8.4.2 Prizer Business Overview
  22. 8.4.3 Prizer Anti-Tuberculosis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Prizer Anti-Tuberculosis Drug Product Portfolio
  24. 8.4.5 Prizer Recent Developments
  25. 8.5 Otsuka
  26. 8.5.1 Otsuka Company Information
  27. 8.5.2 Otsuka Business Overview
  28. 8.5.3 Otsuka Anti-Tuberculosis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Otsuka Anti-Tuberculosis Drug Product Portfolio
  30. 8.5.5 Otsuka Recent Developments
  31. 8.6 Lupin
  32. 8.6.1 Lupin Company Information
  33. 8.6.2 Lupin Business Overview
  34. 8.6.3 Lupin Anti-Tuberculosis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lupin Anti-Tuberculosis Drug Product Portfolio
  36. 8.6.5 Lupin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Tuberculosis Drug Value Chain Analysis
  2. 9.1.1 Anti-Tuberculosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Tuberculosis Drug Sales Mode & Process
  6. 9.2 Anti-Tuberculosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Tuberculosis Drug Distributors
  9. 9.2.3 Anti-Tuberculosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst